StockData
20/20 Biolabs, Inc. logo

20/20 Biolabs, Inc. (AIDX) income statement

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19−0.00 (-1.01%)

Close on Nov 18, 2026Market cap $2.37MP/E –Yield –

20/20 Biolabs, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
29.6%
Operating margin
-162.9%
Net margin
-182.8%
Return on equity, FY2025
-503.1%

Financial strength

Current ratio
1.99
Debt to equity
–
Debt to assets
–
Cash to current liabilities
178.2%

Valuation

P/E ratio
–
Price to sales
1.16
Price to book
1.46
Dividend yield
–

See a number that looks wrong?